HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: jcp.2007.053850v1 61/6/757    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Google Scholar Articles by Di Palma, S Articles by Isola, J PubMed PubMed Citation Articles by Di Palma, S Articles by Isola, J Pubmed/NCBI databases Medline Plus Health Information Breast Cancer

A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer

¹ Department of Histopathology, Royal Surrey County Hospital and University of Surrey, Guildford, Surrey, UK
² Department of Molecular Biology, Royal Surrey County Hospital, Guildford, Surrey, UK
³ Westmead Hospital, Sydney, New South Wales, Australia
⁴ Department of Biomedical Science and Human Oncology, University of Turin, Turin, Italy
⁵ Regina Elena Cancer Institute, Rome, Italy
⁶ MITERA Maternity and Surgical Center, Athens, Greece
⁷ IPATIMUP and Medical Faculty of Porto, Porto, Portugal
⁸ University of Tampere, Tampere, Finland

Correspondence to:
Silvana Di Palma, Department of Histopathology, Royal Surrey County Hospital, Guildford, Surrey, UK; silvana.dipalma{at}royalsurrey.nhs.uk

Background: Chromogenic in situ hybridisation (CISH) is an alternative to immunohistochemistry or FISH for the assessment of HER2 oncogene status in breast cancer. Although CISH is being used increasingly in routine diagnostics, there are no established inter-laboratory quality assurance programmes for this test.

Methods: The reproducibility of HER2 CISH analysis was assessed when performed by seven different centres that use the test routinely in diagnostic service.

Results: The results from 28 cases showed overall concordance of 98.5% (192/195 tests; coefficient 0.91). One of the discrepancies was due to the invasive carcinoma having been cut out in the sections received by two of the centres, and the other two were in the non-amplified/equivocal/low-amplified category.

Conclusion: This is believed to be the first report of a quality assurance study assessing laboratories that use HER2 CISH routinely in clinical diagnostics. The results show that CISH is a robust technique providing a suitable assay for the frontline testing of HER2 status in breast cancer.